SYRE
Spyre TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case: positive pivotal data and favourable regulatory progress push adoption expectations toward the high end of analyst targets, validating a premium multiple and supporting material upside [#SERP-1].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
Binary clinical readout failure or mixed efficacy
Momentum
97
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $54.29 · Bull $73.50 · Bear $40.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-27 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $58.57
Why
Momentum97 · Δ7d +0.2
Value41 · Δ7d +0.1
Sentiment31 · Δ7d +6.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-2.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
31
33% active weight
Current posture
7d trendImproving
Δ7d
+6.6
Δ21d
+12.8
Why this grade
Composite grade B. Momentum 96.5 / Value 41.1 / Sentiment 30.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$6.01B
Beta
3.17
Shares Out
77.59M
P/E (TTM) · Derived
-39.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-28.25
Rev YoY
-100.0%
EPS YoY
+86.4%
Gross Margin
-
Op Margin
-
Net Debt
-$603.09M
Current Ratio
10.90
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology